Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 4/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.41 |
| ▸ | LYPLA1 | O75608 | 1/20 | 0.39 |
| ▸ | LYPLA2 | O95372 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL409284 | 0.78 | LYPLA1 (0.43) | CHRM3CHRM2LYPLA1LYPLA2NPC1 | |
| SCHEMBL19934959 | 0.78 | SLC6A9 (0.44) | CHRM3CHRM2NPC1RAB9ATAAR1 | |
| SCHEMBL24827937 | 0.77 | — | — | |
| SCHEMBL24234532 | 0.74 | CHRM3 (0.38) | CHRM3CHRM2 | |
| SCHEMBL14788270 | 0.72 | HSD11B1 (0.36) | — | |
| SCHEMBL24851527 | 0.71 | CYP2D6 (0.32) | — | |
| SCHEMBL11954981 | 0.67 | MBTD1 (0.52) | ALDH1A1ATM | |
| SCHEMBL24850533 | 0.67 | — | — | |
| SCHEMBL22419367 | 0.67 | CYP2B6 (0.55) | CHRM3CHRM2TAAR1CYP2B6 | |
| SCHEMBL10236431 | 0.67 | ACHE (0.66) | HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180208591-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. | 2018-07-26 | — | — | US | disclosed |
| US-20180134692-A1 | 1,4-PYRIDONE BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134692-A1 | 1,4-PYRIDONE BICYCLIC HETEROARYL COMPOUNDS | CYP4B1, PDXK, CYP1B1 | CHRM3 1879/4885CHRM2 2091/4885LYPLA1 1406/4885 |
| US-20180208591-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | CYP3A5, PAICS, CYP4B1 | CHRM3 3124/4885CHRM2 3619/4885LYPLA1 2872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.